507 related articles for article (PubMed ID: 34833369)
1. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
2. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
[TBL] [Abstract][Full Text] [Related]
5. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
[TBL] [Abstract][Full Text] [Related]
8. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
[TBL] [Abstract][Full Text] [Related]
11. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
12. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
13. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study.
Kurosaki T; Mitani S; Tanaka K; Suzuki S; Kanemura H; Haratani K; Fumita S; Iwasa T; Hayashi H; Yoshida T; Ishikawa K; Kitano M; Otsuki N; Nishimura Y; Doi K; Nakagawa K
Anticancer Drugs; 2021 Jan; 32(1):95-101. PubMed ID: 32976215
[TBL] [Abstract][Full Text] [Related]
16. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
Pestana RC; Becnel M; Rubin ML; Torman DK; Crespo J; Phan J; Hanna E; Bell D; Glisson BS; Johnson JM; Lee JJ; Ferrarotto R
Oral Oncol; 2020 Feb; 101():104523. PubMed ID: 31864957
[TBL] [Abstract][Full Text] [Related]
17. Real-world Data Study of the Efficacy and Toxicity of Nivolumab
Macia-Rivas L; Fernandez-Laguna CL; Alvarez-Asteinza C; Maray I; Carbajales-Alvarez M; Lozano-Blazquez A
Anticancer Res; 2023 Apr; 43(4):1681-1688. PubMed ID: 36974777
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer.
Fukuoka O; Saito Y; Mukai T; Hayashi T; Yamamura K; Sakai T; Kobayashi K; Akashi K; Yoshida M; Ando M; Yamasoba T
Laryngoscope; 2024 Jan; 134(1):228-235. PubMed ID: 37377185
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma.
Okada T; Okamoto I; Sato H; Ito T; Miyake K; Tsukahara K
In Vivo; 2021; 35(2):1253-1259. PubMed ID: 33622928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
